Protein proteinase inhibitor therapy in experimental pancreatitis: pharmacological characterization of the inhibitor.
The pharmacodynamical properties of the duck ovomucoid and its effect on the development of experimental pancreatitis in rats have been studied. It has been shown that after intravenous injection the ovomucoid initially accumulated in the liver, kidneys and blood, while after intraperitoneal injection--mainly in the pancreas and kidneys. The inhibitor is removed from circulation by renal filtration, one-half of the injected protein being removed for 4 hr. For the treatment of experimental pancreatitis two modes of ovomucoid administration were used: intravenous and combined (intravenous/intraperitoneal). The ovomucoid intravenous injection in a dose of 16,300 ATU/kg/24 hr resulted in decrease of both the trypsin-like activity and the level of the trypsinogen activation peptide in the blood to the level in intact rats and also in reduction of the primary pancreas destruction. The same effect observed in the case of the ovomucoid combined injection, but with a lower intravenous dose.
Valueva
T A
TA
A.N.Bach Institute of Biochemistry, Russian Academy of Sciences, Moscow.
Matveev
N L
NL
Mosolov
V V
VV
Penin
V A
VA
D000818:Animals; D004372:Ducks; D007457:Iodine Radioisotopes; D051379:Mice; D008807:Mice, Inbred BALB C; D010059:Ovomucin / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D010195:Pancreatitis / Q000188:drug therapy*; D011865:Radioisotope Dilution Technique; D051381:Rats; D017208:Rats, Wistar; D014018:Tissue Distribution; D014357:Trypsin / Q000097:blood*; D014361:Trypsin Inhibitors / Q000097:blood
D007457:Iodine Radioisotopes; D014361:Trypsin Inhibitors; D010059:Ovomucin; D014357:Trypsin